Only 20 participants received a formal drug allergy evaluation which resulted in the delabeling of 17 drug allergy labels MILWAUKEE, Feb. 13, 2026 /PRNewswire/ -- Drug allergy labels (DAL) are common and largely unevaluated in children with primary immunodeficiencies, which could lead to worse patient outcomes, according to new research being presented at the 2026 AAAAI Annual Meeting. "Drug reactions can be scary for families, particularly for children with primary immunodeficiencies who have

Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026 SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today

Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month. The California drugmaker is dishing out $80 million upfront for GH31, a MAT2A-targeted synthetic lethality drug for select solid tumors. MAT2A plays a role in metabolic regulation and can be overexpressed in cancer cells. Genhouse could get up to $1.45 billion in biobucks, the company announced Friday on WeChat. A Gilead spokesperson

The Pentagon on Friday briefly added WuXi AppTec to a list of companies that aid the Chinese military before withdrawing the filing with no explanation. If the list is reposted as is, the designation would heighten scrutiny of the biotech supplier and make it a target of the recently passed Biosecure Act that restricts federal contracts with biopharma suppliers that are deemed foreign adversaries. Biosecure defers to the Pentagon’s 1260H list of Chinese military companies. The ultimate decision

SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness. "We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale

London, Mayfair based Norisia introduces a more intelligent and considered approach to daily wellness, uniting artificial intelligence with human bioscience. Artificial intelligence allows us to analyse biomedical research at scale while maintaining scientific discipline and structural integrity in every model we develop.” — Dr Obi Okeke, Biochemist LONDON, UNITED KINGDOM, MAYFAIR, UNITED KINGDOM, February 13, 2026 / EINPresswire.com / -- London, United Kingdom – Norisia, a Mayfair based healthc

Eli Lilly and Innovent's $8.8 billion new partnership, China's indictment of AstraZeneca and Madrigal Pharmaceuticals' latest metabolic dysfunction-associated steatohepatitis deal made our news this week. Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. China has indicted AstraZeneca and its former top exec in the country following investigations that emerged in 2024. Madrigal has signed a potential $4.4 billion siRNA deal with a Chinese biotech. And mo

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update. "The first quarter of fiscal 2026 ma

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into a single, intelligent system for spine surgery. Continue Reading Stealth AXiS™ surgical system The Stealth AXiS™ system is cleared for spine procedures in the United States, with an underlying arc

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provide